
Roche and Prothena to Advance Prasinezumab in P-IIb Study for Patients with Early Parkinson’s Disease
Shots: The companies will advance the prasinezumab into a P-IIb study in patients with early Parkinson’s disease based on positive signals of efficacy consistent with […]